Cargando…

Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations

BACKGROUND: In Parkinson’s disease (PD), there is heterogeneity in the clinical presentation and underlying biology. Research on PD subtypes aims to understand this heterogeneity with potential contribution for the knowledge of disease pathophysiology, natural history and therapeutic development. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mestre, Tiago A., Fereshtehnejad, Seyed-Mohammad, Berg, Daniela, Bohnen, Nicolaas I., Dujardin, Kathy, Erro, Roberto, Espay, Alberto J., Halliday, Glenda, van Hilten, Jacobus J., Hu, Michele T., Jeon, Beomseok, Klein, Christine, Leentjens, Albert F.G., Marinus, Johan, Mollenhauer, Brit, Postuma, Ronald, Rajalingam, Rajasumi, Rodríguez-Violante, Mayela, Simuni, Tanya, Surmeier, D. James, Weintraub, Daniel, McDermott, Michael P., Lawton, Michael, Marras, Connie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150501/ https://www.ncbi.nlm.nih.gov/pubmed/33682731 http://dx.doi.org/10.3233/JPD-202472

Ejemplares similares

Punding in Parkinson's Disease: An Update
por: Rajalingam, Rajasumi, et al.
Publicado: (2023)

Editorial: Managing Parkinson's Disease With a Multidisciplinary Perspective
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2021)

Gender Differences in the Prevalence of Parkinson's Disease
por: Zirra, Alexandra, et al.
Publicado: (2022)

Gait Analysis in Idiopathic Normal Pressure Hydrocephalus: A Meta‐Analysis
por: Passaretti, Massimiliano, et al.
Publicado: (2023)

COVID-19 and Integrated Multidisciplinary Care Model in Parkinson’s Disease: Literature Review & Future Perspectives
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2022)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Anxiety in Parkinson’s Disease Is Associated with Changes in Brain Structural Connectivity
por: Carey, Guillaume, et al.
Publicado: (2023)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Dopaminergic Vulnerability and Motor Impairments in Older Adults: Need for Targeted Pharmacotherapy
por: Bohnen, Nicolaas
Publicado: (2020)

Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
por: Rodríguez-Violante, Mayela, et al.
Publicado: (2019)

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
por: Venuto, Charles S., et al.
Publicado: (2021)

Cautionary optimism: caffeine and Parkinson’s disease risk
por: Sokol, Leonard L., et al.
Publicado: (2016)

Biomarkers in biological fluids for dementia with Lewy bodies
por: Schade, Sebastian, et al.
Publicado: (2014)

Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review
por: Carey, Guillaume, et al.
Publicado: (2020)

Identifying prodromal symptoms at high specificity for Parkinson’s disease
por: Jackson, Holly, et al.
Publicado: (2023)

The ePark study protocol: A decentralized trial of individual video-assisted cognitive behavioural therapy for depressive disorder in Parkinson's disease
por: Erga, Aleksander H., et al.
Publicado: (2023)

Corrigendum to “The ePark study protocol: A decentralized trial of individual video-assisted cognitive behavioural therapy for depressive disorder in Parkinson's disease” [Contemp. Clinic. Trials Commun. 32 (2023) 101080]
por: Erga, Aleksander H., et al.
Publicado: (2023)

Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease
por: Zhu, Kangdi, et al.
Publicado: (2016)

Editorial: Patient Empowerment and Person-Centered Care in Movement Disorders
por: Ramirez-Zamora, Adolfo, et al.
Publicado: (2020)

Ketogenic interventions in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease: A systematic review and critical appraisal
por: Bohnen, Jeffrey L. B., et al.
Publicado: (2023)

Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease
por: Zeighami, Yashar, et al.
Publicado: (2019)

Gait in Parkinson's Disease
por: Martinez-Ramirez, Daniel, et al.
Publicado: (2019)

Editorial: Measurement Tools for Clinical Assessment, Characterization and Neurorehabilitation of Parkinson's Disease
por: Rodriguez-Blazquez, Carmen, et al.
Publicado: (2021)

Predicting severity and prognosis in Parkinson's disease from brain microstructure and connectivity
por: Abbasi, Nooshin, et al.
Publicado: (2019)

Non-Dopaminergic Therapies
por: Nutt, John G., et al.
Publicado: (2018)

Dopaminergic Signaling: Driver of Mobility Resilience and Moderator of Response to Pharmacotherapy
por: Rosano, Caterina, et al.
Publicado: (2020)

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination
por: Li, Juan, et al.
Publicado: (2022)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2019)

Assessing Walking Adaptability in Parkinson's Disease: “The Interactive Walkway”
por: Geerse, Daphne J., et al.
Publicado: (2018)

Self-reported olfactory dysfunction in Mexican healthcare workers during the first six months of the COVID-19 pandemic: A nationwide online survey study
por: Delgado-Garcia, Guillermo, et al.
Publicado: (2021)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients
por: Dadar, Mahsa, et al.
Publicado: (2018)

GAIT SLOWING AMONG FRAIL OLDER ADULTS: IS HIGHER DOPAMINERGIC SIGNALING PROTECTIVE?
por: Rosano, Caterina, et al.
Publicado: (2019)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
por: Chahine, L. M., et al.
Publicado: (2019)

Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease Induces Functional Brain Changes
por: Carey, Guillaume, et al.
Publicado: (2023)

Review of Hereditary and Acquired Rare Choreas
por: Martinez-Ramirez, Daniel, et al.
Publicado: (2020)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v4efonf36g7t419vnivjhvo7i3